Registration Number
0213U004936,
0110U001824
, R & D reports
Title
Clinical, epidemiological and immunological study to improve preventive and medical technologies in influenza and other acute respiratory viral infections
popup.stage_title
Head
Kovalchuk Leonid Ya., Andreychyn Michael Antonovich,
Registration Date
09-01-2014
Organization
Ternopol State Medical University by I.Ya.Horbachevsky
popup.description2
The SLIAR-model of ARVI epidemic is examined. The terms of local asymptotic firmness of steady-state which answers absence of disease are got. The model of coexistence of two cultures of virus is also considered, which the terms of firmness of three steady-states are presented for. The terms of firmness are expressed in terms of indexes of genesialness of viruses. High efficiency of anthipoxsants in therapy of modelled ARDS is found, that became subsoil for researches in this direction. Comparison of results of PLR and MFA "Amplisens" (Russia) test systems testifies about higher informing of PLR at the timely fence of material, and also about the insufficient sensitiveness of PLR according to the exposure of adenoviruses. Clinical antiviral efficiency of remantadin for patients with a flu on a background of chronic obstructive illness of lungs is studied , and also influence of treatment on the immune answer, and frequency of complications development. High efficiency and good portable of rimavir is well-proven for such patients. Confirmed not only positive influence on course of flu but also on immune status of patients, risk of complications development and necessity of the use of antibiotics. Clinical-immune features of viral-bacterial pneumonias which observed in 34 patients with A H1N1 influenza are resulted. It is marked, that viral-bacterial pneumonias have clear anamnestic, clinical and laboratory differences in comparing to typical bacterial pneumonias, that allows easily enough to differentiate them even to the receipt of results of microbiological confirmation. Criteria which allow prognose the severe course of disease are set. It is well-proven that for patients with severe viral-bacterial pneumonia effective early intravein introduction of immunoprotein biotvein in dose 2 mg/kg during 3-5 days. Addition of base therapy of patients with a flu and other ARVI by altabor in a dose 2 tab for 20 mg 4 times per days within a week accompanied substantial advantage by comparison to only by base therapy after the row of signs: at the greater amount of patients convalescence came to 7 days, a cough regressed quick, relatively rarer there were complications. After 7 days of altabor application the level of leucocytes and relative maintenance of neutrophils and lymphocytes was normalized, leucocytar index of intoxication increased, approaching normal values; the index of leucocytes change increased; lymphocytar index decrease substantially, approaching a norm. Such treatment provided reduction of immunological violations, discovered to treatment yet and. Amount of leucocytes increased and maintenance of lymphocytes was normalized, concentration of IGA and lysocim was normal, and also normalized the level of interferons/ On a background of аltabor application in a therapeutic dose by-reactions arose up all in 3 (3,33 %) from 90 patients, which was classified as credible, supposed and not serious.
Product Description
popup.authors
Івахів Олег Любомирівна
Іщук Інна Станіславівна
Васильєва Наталія Абрамівна
Гевкалюк Наталія Олександрівна
Гнатів Володимир Володимирович
Господарський Ігор Ярославович
Завіднюк Наталя Григорівна
Качор Василь Олексійович
Кліщ Іван Миколайович
Климнюк Сергій Іванович
Копча Василь Степанович
Коробко Дмитро Борисович
Кучвара Олександра Мирославівна
Марценюк Василь Петрович
Ничик Наталя Анатоліївна
Олійник Олександр Валентинович
Посохова Катерина Андріївна
Стаханський Олександр Олександрович
popup.nrat_date
2020-04-02
